Amylyx Pharmaceuticals Files Annual Report
Ticker: AMLX · Form: ARS · Filed: Apr 23, 2026 · CIK: 0001658551
Sentiment: neutral
Topics: annual-report, sec-filing
TL;DR
Amylyx dropped its 2025 ARS filing on 4/23/26. Check it out.
AI Summary
Amylyx Pharmaceuticals, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The filing includes the complete submission text file and the ARS document itself. The company's principal executive offices are located at 55 Cambridge Parkway, Suite 6W, Cambridge, MA 02142.
Why It Matters
This filing provides shareholders with an official overview of the company's performance and financial standing for the fiscal year 2025.
Risk Assessment
Risk Level: low — This is a routine annual filing and does not contain new material information that would immediately impact the stock price.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Filer
- 0001658551 (company) — CIK Number
- 2026-04-23 (date) — Filing Date
- 2025-12-31 (date) — Period of Report
- 55 Cambridge Parkway Suite 6W (location) — Mailing and Business Address
- Cambridge, MA 02142 (location) — Mailing and Business Address
FAQ
What is the form type and accession number for this filing?
The form type is ARS (Annual Report to Security Holders) and the SEC Accession No. is 0001193125-26-171809.
When was this ARS filing accepted by the SEC?
This ARS filing was accepted on 2026-04-23 at 07:03:13.
What period does this Annual Report to Security Holders cover?
The period of report for this ARS filing is 2025-12-31.
What is Amylyx Pharmaceuticals, Inc.'s business address?
Amylyx Pharmaceuticals, Inc.'s business address is 55 Cambridge Parkway Suite 6W, Cambridge MA 02142.
What is the CIK number for Amylyx Pharmaceuticals, Inc.?
The CIK number for Amylyx Pharmaceuticals, Inc. is 0001658551.
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 23, 2026 regarding Amylyx Pharmaceuticals, Inc. (AMLX).